Dr. Lori Davis, MD

Claim this profile

Tuscaloosa VA Medical Center, Tuscaloosa, AL

Studies Attention-Deficit/Hyperactivity Disorder (ADHD)
Studies Traumatic Brain Injury
2 reported clinical trials
4 drugs studied

Affiliated Hospitals

Image of trial facility.

Tuscaloosa VA Medical Center, Tuscaloosa, AL

Clinical Trials Lori Davis, MD is currently running

Image of trial facility.

Methylphenidate

for Post-Traumatic Stress Disorder

Posttraumatic stress disorder (PTSD) is frequently accompanied by difficulty concentrating, poor memory, and inability to keep up with tasks, which negatively impacts a person's ability to function at work and in relationships. Currently available treatments do not fully relieve all symptoms. A published research report showed positive evidence that the stimulant medication methylphenidate was beneficial in treating these problems. This study will evaluate the ability of methylphenidate to treat PTSD and associated neurocognitive complaints in Veterans. An innovative feature is the study's N-of-1 design. In this design, every participant will move back and forth every 4-5 weeks between treatment with methylphenidate and treatment with placebo, in random order and under double-blind conditions, over a 20-week period. The investigators will compare the aggregated change in PTSD and neurocognitive symptoms between periods of treatment with methylphenidate versus placebo. Results will help clinicians to better choose the best treatment for Veterans living with PTSD.

Recruiting

2 awards

Phase 4

Image of trial facility.

Buprenorphine Forms

for Opioid Use Disorder

VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.

Recruiting

3 awards

Phase 4

3 criteria

More about Lori Davis, MD

Clinical Trial Related

1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Lori Davis, MD has experience with

  • Methylphenidate
  • Placebo
  • Injectable Subcutaneous Buprenorphine
  • Sublingual Buprenorphine With Naloxone

Breakdown of trials Lori Davis, MD has run

Attention-Deficit/Hyperactivity Disorder (ADHD)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Lori Davis, MD specialize in?

Is Lori Davis, MD currently recruiting for clinical trials?

Are there any treatments that Lori Davis, MD has studied deeply?

What is the best way to schedule an appointment with Lori Davis, MD?

What is the office address of Lori Davis, MD?

Is there any support for travel costs?